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Risk of MACE
Control of inflammation has been proposed to help reduce 
cardiovascular morbidity, and studies have revealed a car-
dioprotective effect for the systemic agents methotrexate and 
anti–tumor necrosis factor (TNF)-α in rheumatoid arthritis and 
psoriasis. Ryan and colleagues performed a meta-analysis of 22 
randomized controlled trials of anti-IL-12/23 agents (ustekinu-
mab and briakinumab) and TNF-α agents in order to evaluate 
the potential association between these chronic plaque psoria-
sis therapies and major adverse cardiovascular events (MACEs). 
Together, these studies comprised 10,183 patients. During the 
placebo-controlled phases of the IL-12/23 agent studies, 10 
MACEs were reported in treated patients (n = 3,179), whereas 
no events were reported in the placebo group (n = 1,474). In 
studies of the anti-TNF-α agents, one treated patient (n = 3,858) 
and one placebo-treated patient (n = 1,812) experienced a 
MACE. These findings do not support an increased risk of 
MACEs associated with the use of anti-IL-12/23 or anti-TNF-α 
agents, although the small number of events may have resulted 
in an underpowered study. (JAMA 306:864–71, 2011) Selected 
by H. Williams
Culpability of T cells
Although desmoglein 3 (Dsg3) has been identified as the IgG-
targeted autoantigen in pemphigus vulgaris (PV), the recent 
isolation of Dsg3-specific CD4+ T cells from Dsg3−/− mice led 
Takahashi and colleagues to investigate the pathogenic role of 
these T cells in PV. Cotransfer of T cells from mice engineered to 
express Dsg3-specific T-cell receptors developed in the absence 
of Dsg3 and Dsg3−/− B cells resulted in a severe skin phenotype 
that mimicked paraneoplastic pemphigus (PNP). Interestingly, 
this transfer also resulted in direct infiltration of the transgenic 
T cells in the skin in a manner that recapitulated interface 
dermatitis, which is characteristic of PNP but not PV. In addition, 
retrovirally generated Dsg3-specific T cells induced interface 
dermatitis without B cells, and this effect was dependent on 
IFN-γ. Thus, T cells that are specific for a single autoantigen 
essential for maintaining epithelial integrity in the skin are 
capable of inducing interface dermatitis. These cardinal findings 
open up a new avenue for studying the immunopathophysio-
logy of T cell–mediated skin diseases. (J Clin Invest 121:3677–
88, 2011) Selected by P. Bergstresser
Mosaic effects
Previous reports suggested that Proteus syndrome, which is 
characterized by patchy or segmental overgrowth and hyper-
plasia of various tissues, is caused by a constitutively lethal 
somatic mutation. Lindhurst and colleagues recently employed 
exome sequencing of 158 samples from 29 patients with 
Proteus syndrome to identify an underlying somatic mutation. 
A variant of AKT1 (c.49GàA) was identified in seven analyzed 
exomes from four patients. The findings were validated in addi-
tional patient samples with a total of 26 of 29 Proteus syndrome 
patients containing this mutation, and the mutant allele was 
present in these samples in a range from 1 to 50%. Furthermore, 
this mutation was associated with increased levels of phosphory-
lation of the AKT1 gene product, AKT1 kinase. Together, these 
findings indicate that the AKT1 mutation causes Proteus syn-
drome and support the hypothesis that this syndrome is the result 
of somatic mosaicism for a mutation that is lethal in the nonmo-
saic state. (N Engl J Med 365:611–9, 2011) Selected by J. Uitto
Just call me DITRA
The genetic abnormalities underlying familial generalized pus-
tular psoriasis are unknown, despite the inclusion of this life-
threatening multisystemic inflammatory disease within the 
spectrum of psoriasis vulgaris because of the presence of a dif-
fuse, erythematous, pustular rash. Using homozygosity mapping 
and direct sequencing of nine Tunisian multiplex families with 
autosomal recessive generalized pustular psoriasis, Marrakchi 
and colleagues identified a homozygous variant in IL36RN, the 
gene that encodes the IL-36-receptor antagonist IL-36Ra. Based 
on structural predictions, this L27P mutation affects the stability 
of this protein, alters its affinity for its receptor, and ultimately 
decreases its inhibitory activity. The studies showed that aber-
rant IL-36Ra causes unregulated secretion of inflammatory cyto-
kines and results in generalized pustular psoriasis. Based on 
the nomenclature for a disease with mutations in IL-1 receptor 
antagonist (DIRA), the authors suggest that this disease now be 
called DITRA (deficiency of interleukin 36–receptor antagonist). 
(N Engl J Med 365:620–8, 2011) Selected by J. Uitto
WHO knows best?
Studies suggesting that exclusive breastfeeding confers protec-
tion against allergies, including eczema, in infants, propelled 
the World Health Organization the UK Department of Health, 
and other organizations to endorse weaning as late as 6 months. 
After additional studies with conflicting results, Flohr and col-
leagues examined the effects of breastfeeding on childhood 
eczema among the 51,119 children in the International Study 
of Asthma and Allergies in Childhood (ISAAC) Phase Two, a 
worldwide—and the largest—data set on this topic. No evi-
dence exists that exclusive breastfeeding for 4 months or longer 
protects infants against childhood eczema. Breastfeeding did 
confer a risk reduction in more severe sleep-disturbed ecze-
ma, but this effect was lost when infants were breastfed for 
longer than 4 months. These findings thus suggest that breast-
feeding guidelines with regard to eczema be reexamined. 
Furthermore, additional studies into the timing of introducing 
solid foods alongside breastfeeding are needed. (Br J Dermatol, 
published online 24 August 2011; doi:10.1111/j.1365-
2133.2011.10588.x) Selected by P. Bergstresser
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